| Russell C Reeves, MD | |
|
3980 Colonnade Pkwy, Birmingham, AL 35243-2382 | |
| (205) 510-5000 | |
| Not Available |
| Full Name | Russell C Reeves |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 50 Years |
| Location | 3980 Colonnade Pkwy, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740279348 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 7146 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brookwood Baptist Medical Center | Birmingham, AL | Hospital |
| Grandview Medical Center | Birmingham, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Health Centers Llc | 3476457011 | 156 |
News Archive
Research published in the September 2009 issue of the Journal of Thoracic Oncology has found that narrow-band imaging bronchoscopy increases the specificity of bronchoscopic early lung cancer detection and can serve as an alternative detection device.
Point Loma Nazarene University is now accepting applications for its Kyoto Prize Journalism Fellowship, a unique learning opportunity for a journalist who has worked to attain a level of excellence in his or her field and hopes to further integrity in the sciences and arts. The selected journalist will attend the 26th annual Kyoto Prize presentation ceremony and will interact with the latest Kyoto Prize laureates in Kyoto, Japan, November 7-14, 2010.
University of Miami Psychologist Alexandra L. Quittner leads one of the largest, most nationally representative studies of the effects of parenting on very young, deaf children who have received cochlear implants.
Researchers from The University of Texas Medical Branch at Galveston, led by prostate cancer treatment pioneer Dr. Eric Walser, have shown that selectively destroying cancerous prostate tissue is as effective as complete prostate removal or radiation therapy while preserving more sexual and urinary function than the other treatments.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
› Verified 3 days ago
| Entity Name | Bw Cardiology, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366816068 PECOS PAC ID: 6608185749 Enrollment ID: O20151012002260 |
News Archive
Research published in the September 2009 issue of the Journal of Thoracic Oncology has found that narrow-band imaging bronchoscopy increases the specificity of bronchoscopic early lung cancer detection and can serve as an alternative detection device.
Point Loma Nazarene University is now accepting applications for its Kyoto Prize Journalism Fellowship, a unique learning opportunity for a journalist who has worked to attain a level of excellence in his or her field and hopes to further integrity in the sciences and arts. The selected journalist will attend the 26th annual Kyoto Prize presentation ceremony and will interact with the latest Kyoto Prize laureates in Kyoto, Japan, November 7-14, 2010.
University of Miami Psychologist Alexandra L. Quittner leads one of the largest, most nationally representative studies of the effects of parenting on very young, deaf children who have received cochlear implants.
Researchers from The University of Texas Medical Branch at Galveston, led by prostate cancer treatment pioneer Dr. Eric Walser, have shown that selectively destroying cancerous prostate tissue is as effective as complete prostate removal or radiation therapy while preserving more sexual and urinary function than the other treatments.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
› Verified 3 days ago
| Entity Name | Baptist Health Centers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265496236 PECOS PAC ID: 3476457011 Enrollment ID: O20180124001442 |
News Archive
Research published in the September 2009 issue of the Journal of Thoracic Oncology has found that narrow-band imaging bronchoscopy increases the specificity of bronchoscopic early lung cancer detection and can serve as an alternative detection device.
Point Loma Nazarene University is now accepting applications for its Kyoto Prize Journalism Fellowship, a unique learning opportunity for a journalist who has worked to attain a level of excellence in his or her field and hopes to further integrity in the sciences and arts. The selected journalist will attend the 26th annual Kyoto Prize presentation ceremony and will interact with the latest Kyoto Prize laureates in Kyoto, Japan, November 7-14, 2010.
University of Miami Psychologist Alexandra L. Quittner leads one of the largest, most nationally representative studies of the effects of parenting on very young, deaf children who have received cochlear implants.
Researchers from The University of Texas Medical Branch at Galveston, led by prostate cancer treatment pioneer Dr. Eric Walser, have shown that selectively destroying cancerous prostate tissue is as effective as complete prostate removal or radiation therapy while preserving more sexual and urinary function than the other treatments.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Russell C Reeves, MD 3980 Colonnade Pkwy, Birmingham, AL 35243-2382 Ph: (205) 510-5000 | Russell C Reeves, MD 3980 Colonnade Pkwy, Birmingham, AL 35243-2382 Ph: (205) 510-5000 |
News Archive
Research published in the September 2009 issue of the Journal of Thoracic Oncology has found that narrow-band imaging bronchoscopy increases the specificity of bronchoscopic early lung cancer detection and can serve as an alternative detection device.
Point Loma Nazarene University is now accepting applications for its Kyoto Prize Journalism Fellowship, a unique learning opportunity for a journalist who has worked to attain a level of excellence in his or her field and hopes to further integrity in the sciences and arts. The selected journalist will attend the 26th annual Kyoto Prize presentation ceremony and will interact with the latest Kyoto Prize laureates in Kyoto, Japan, November 7-14, 2010.
University of Miami Psychologist Alexandra L. Quittner leads one of the largest, most nationally representative studies of the effects of parenting on very young, deaf children who have received cochlear implants.
Researchers from The University of Texas Medical Branch at Galveston, led by prostate cancer treatment pioneer Dr. Eric Walser, have shown that selectively destroying cancerous prostate tissue is as effective as complete prostate removal or radiation therapy while preserving more sexual and urinary function than the other treatments.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.
› Verified 3 days ago
Juan Mario Bernal, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3680 Grandview Pkwy Ste 200, Birmingham, AL 35243 Phone: 205-971-7500 | |
Dr. William Randolph Maddox, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 701 Princeton Ave Sw, Birmingham, AL 35211 Phone: 205-783-3000 Fax: 205-297-9411 | |
Jodie Ann Dionne, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 703 19th St S Bldg 206, Birmingham, AL 35233 Phone: 205-975-6530 | |
Dr. Karl Tullio Schroeder, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 817 Princeton Ave Sw Ste 199, Birmingham, AL 35211 Phone: 205-780-1920 Fax: 205-780-2345 | |
Dr. Deepti Bahl, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2000 6th Ave S, Birmingham, AL 35233 Phone: 205-934-9999 | |
Amitkumar Mehta, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1720 2nd Ave S # Np2540t, Birmingham, AL 35294 Phone: 205-996-8400 Fax: 205-934-1608 | |
Shana Monika Machado, D.O. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-4011 |